Skip to main content
S 2030 114th Congress Senate Health Drug safety, medical device, and laboratory regulation Drug therapy Genetics

Advancing Targeted Therapies for Rare Diseases Act of 2015

Introduced: September 15, 2015 Introduced by: Bennet, Michael F. Democratic · Colorado See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 114th Congress ended
It never became law before the 114th Congress (2015–2016) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 5 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 5, 2016
Placed on Senate Legislative Calendar under General Orders. Calendar No. 416.
Apr 5, 2016
Committee on Health, Education, Labor, and Pensions. Reported by Senator Alexander with an amendment in the nature of a substitute. Without written report.
Feb 9, 2016
Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature of a substitute favorably.
Sep 15, 2015
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sep 15, 2015
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Advancing Targeted Therapies for Rare Diseases Act of 2016

(Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act to permit the Food and Drug Administration to allow the sponsor of a new drug or biological product for the treatment of a rare, serious condition to rely upon information submitted for an approved medication that uses the same technology. For a sponsor to be eligible to rely upon submitted information: (1) the sponsor must have developed, or have a right of reference to, the relied upon information; and (2) the new medication must use nucleic acids (e.g., DNA) or similar chemicals, or must affect a disease-causing product of a mutated gene (e.g., the protein that causes cystic fibrosis).
What's happening now April 5, 2016

Placed on Senate Legislative Calendar under General Orders. Calendar No. 416.

 Related & companion bills 1
  • HR 34 Related bill 21st Century Cures Act
 Bill text 2 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Democratic 1
D
Warren, Elizabeth
Massachusetts · Sep 15, 2015
Cite this page click to expand
APA
U.S. Congress. (2026). S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016. 114th Congress. Open America. https://openamerica.io/bill/114-S-2030/
MLA
"S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016." 114th Congress, 2026, Open America, https://openamerica.io/bill/114-S-2030/.
Bluebook (legal)
S. 2030, 114th Cong. (2026), https://openamerica.io/bill/114-S-2030/.
Markdown link
[S. 2030: Advancing Targeted Therapies for Rare Diseases Act of 2016](https://openamerica.io/bill/114-S-2030/)
Report a problem